Guyasuta Investment Advisors Inc. Sells 963 Shares of AbbVie Inc (NYSE:ABBV)

Guyasuta Investment Advisors Inc. decreased its position in shares of AbbVie Inc (NYSE:ABBV) by 4.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 22,619 shares of the company’s stock after selling 963 shares during the quarter. Guyasuta Investment Advisors Inc.’s holdings in AbbVie were worth $2,085,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Penserra Capital Management LLC bought a new stake in shares of AbbVie during the fourth quarter valued at approximately $32,000. Larson Financial Group LLC bought a new stake in AbbVie in the fourth quarter worth $37,000. Horrell Capital Management Inc. bought a new stake in AbbVie in the fourth quarter worth $41,000. Portfolio Solutions LLC bought a new stake in AbbVie in the fourth quarter worth $46,000. Finally, Signet Investment Advisory Group Inc. bought a new stake in AbbVie in the fourth quarter worth $62,000. Institutional investors own 70.53% of the company’s stock.

ABBV has been the topic of several analyst reports. UBS Group reissued a “neutral” rating and issued a $91.00 target price (down from $97.00) on shares of AbbVie in a report on Wednesday, January 23rd. Zacks Investment Research downgraded AbbVie from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. ValuEngine cut AbbVie from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Credit Suisse Group set a $79.00 price target on AbbVie and gave the stock a “hold” rating in a research note on Friday, January 25th. Finally, Barclays restated a “hold” rating and issued a $86.00 price target on shares of AbbVie in a research note on Thursday, February 14th. Six investment analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. AbbVie presently has an average rating of “Hold” and an average price target of $94.95.

AbbVie stock traded up $0.71 during mid-day trading on Wednesday, reaching $81.59. 4,120,348 shares of the stock traded hands, compared to its average volume of 6,332,157. The stock has a market cap of $119.57 billion, a PE ratio of 10.31, a price-to-earnings-growth ratio of 1.62 and a beta of 1.14. AbbVie Inc has a 12-month low of $75.62 and a 12-month high of $106.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.08. AbbVie had a negative return on equity of 221.09% and a net margin of 16.42%. The business had revenue of $7.83 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the previous year, the company posted $1.87 earnings per share. AbbVie’s revenue for the quarter was down 1.3% on a year-over-year basis. Equities research analysts anticipate that AbbVie Inc will post 8.83 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th were issued a dividend of $1.07 per share. This represents a $4.28 annualized dividend and a yield of 5.25%. The ex-dividend date was Friday, April 12th. AbbVie’s dividend payout ratio is presently 54.11%.

In other AbbVie news, Vice Chairman Laura J. Schumacher sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $80.00, for a total transaction of $2,000,000.00. Following the completion of the sale, the insider now owns 139,838 shares of the company’s stock, valued at $11,187,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 15,797 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $79.03, for a total value of $1,248,436.91. Following the sale, the executive vice president now directly owns 93,312 shares of the company’s stock, valued at approximately $7,374,447.36. The disclosure for this sale can be found here. Insiders have sold 41,272 shares of company stock valued at $3,286,290 in the last three months. 0.08% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Guyasuta Investment Advisors Inc. Sells 963 Shares of AbbVie Inc (NYSE:ABBV)” was originally reported by Sundance Herald and is the property of of Sundance Herald. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://sundanceherald.com/2019/05/22/abbvie-inc-abbv-shares-sold-by-guyasuta-investment-advisors-inc.html.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Featured Story: Quiet Period Expirations Explained

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply